医学
不利影响
随机对照试验
内科学
PCSK9
药理学
临床试验
临床研究阶段
随机化
前蛋白转化酶
作者
Christie M. Ballantyne,Puja Banka,Gustavo Méndez,Raymundo Garcia,Julio Rosenstock,Anthony Rodgers,Geraldine Mendizabal,Yale Mitchel,Alberico L. Catapano
标识
DOI：10.1016/j.jacc.2023.02.018
摘要
MK-0616 demonstrated statistically significant and robust, dose-dependent placebo-adjusted reductions in LDL-C at Week 8 of up to 60.9% from baseline and was well tolerated during 8 weeks of treatment and an additional 8 weeks of follow-up. (A Study of the Efficacy and Safety of MK-0616 [Oral PCSK9 Inhibitor] in Adults With Hypercholesterolemia [MK-0616-008]; NCT05261126).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
浮游
无极微光
xxfsx
yznfly
吴彦祖
归尘
ccm
寻道图强
tuanheqi
子车茗
yang
且慢
qingmoheng
GingerF
sevenhill
彭于彦祖
Frank
BareBear
chenqiumu
热心市民小红花
Mic
蜀安
Dean
专注的问寒
皖公网安备34019202002308
